EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)

Abhinav Vasudevan iD, Danny Con iD, Peter De Cruz iD, Miles P Sparrow iD, Antony B Friedman iD, Mayur Garg, Soleiman Kashkooli, Peter R Gibson, Daniel R van Langenberg iD

Alimentary Pharmacology & Therapeutics · 2024-02 · 59 (4) · 504-514

DOI: 10.1111/apt.17831 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 14.12.2023. Verfasst von Abhinav Vasudevan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia. Hauptthemen laut MEDLINE: Azathioprine, Inflammatory Bowel Diseases, Purines, Sulfhydryl Compounds. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thiopurines are established treatments for inflammatory bowel disease (IBD), yet concerns remain regarding their safety.

Aim

To evaluate the use of thiopurine‐allopurinol combination therapy compared to standard thiopurine therapy in IBD.

Methods

We performed a multicentre, randomised, placebo‐controlled trial to compare the efficacy and safety of thiopurine‐allopurinol versus thiopurine with placebo for adults commencing a thiopurine for IBD. Patients had active disease at baseline; dosing of therapy was based on a pre‐specified regimen and subsequent metabolites. The primary outcome was the proportion of patients achieving a composite of symptomatic disease activity remission (Harvey Bradshaw Index

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzathioprineInflammatory Bowel DiseasesPurinesSulfhydryl CompoundsAdultHumansFemaleMiddle AgedMaleAllopurinolMercaptopurineImmunosuppressive AgentsTreatment OutcomeDrug Therapy, CombinationImmunologic Factors

Substanzen

AzathioprineAllopurinolMercaptopurineImmunosuppressive Agents2-mercaptopurineImmunologic FactorsPurinesSulfhydryl Compounds

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia.
  • Monash University, Eastern Health Clinical School, Box Hill, Victoria, Australia.
  • Department of Gastroenterology, The Austin Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, Central Clinical School, Monash University and Alfred Health, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, Northern Health, Epping, Victoria, Australia.

ORCID-Profile: Abhinav Vasudevan, Danny Con, Peter De Cruz, Miles P Sparrow, Antony B Friedman, Daniel R van Langenberg

Zitieren

APA

Vasudevan, A., Con, D., De Cruz, P., Sparrow, M. P., Friedman, A. B., Garg, M., Kashkooli, S., Gibson, P. R., & van Langenberg, D. R. (2024). Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). Alimentary Pharmacology & Therapeutics, 59(4), 504-514. https://doi.org/10.1111/apt.17831

Vancouver

Vasudevan A, Con D, De Cruz P, Sparrow MP, Friedman AB, Garg M, et al. Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). Alimentary Pharmacology & Therapeutics. 2024;59(4):504-514. doi:10.1111/apt.17831

BibTeX
@article{Vasudevan2024,
  author = {Vasudevan, Abhinav and Con, Danny and De Cruz, Peter and Sparrow, Miles P and Friedman, Antony B and Garg, Mayur and Kashkooli, Soleiman and Gibson, Peter R and van Langenberg, Daniel R},
  title = {Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {4},
  pages = {504--514},
  doi = {10.1111/apt.17831}
}
Kostenlos starten →